Trastuzumab in gastric cancer

European Journal of Cancer

Volumn 46, Issue 11, 2010, Pages 1949-1959

  Okines, Alicia F C ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Adenocarcinoma; Cisplatin; erbB 2; Fluorescent in situ hybridisation (FISH); Fluoropyrimidine; Gastric cancer; HER 2; Immunohistochemistry (IHC); Oesophagogastric junction; Trastuzumab

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE; ANTINEOPLASTIC METAL COMPLEX; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC CANCER; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; ESOPHAGUS CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART DISEASE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOADING DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SCORING SYSTEM; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; FORECASTING; GENES, ERBB-2; HUMANS; MULTICENTER STUDIES AS TOPIC; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 77954217471     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.05.003     Document Type: Article

References (99)

1. J. Ferlay, P. Autier, and M. Boniol Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 3 2007 581 592
2. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 New Engl J Med 344 11 2001 783 792
3. F. Kamangar, G.M. Dores, and W.F. Anderson Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 14 2006 2137 2150
4. D. Cunningham, W.H. Allum, and S.P. Stenning Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer New Engl J Med 355 1 2006 11 20
5. J.S. Macdonald, S.R. Smalley, and J. Benedetti Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction New Engl J Med 345 10 2001 725 730
6. S. Sakuramoto, M. Sasako, and T. Yamaguchi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine New Engl J Med 357 18 2007 1810 1820
7. A.M. Murad, F.F. Santiago, and A. Petroianu Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 1 1993 37 41
8. S. Pyrhonen, T. Kuitunen, P. Nyandoto, and M. Kouri Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Brit J Cancer 71 3 1995 587 591
9. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;3:CD004064.
10. P. Ross, M. Nicolson, and D. Cunningham Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer J Clin Oncol 20 8 2002 1996 2004 (Pubitemid 34413593)
11. A. Webb, D. Cunningham, and J.H. Scarffe Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 1 1997 261 267
12. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer New Engl J Med 358 1 2008 36 46
13. E. Van Cutsem, V.M. Moiseyenko, and S. Tjulandin Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 31 2006 4991 4997
14. N. Boku, S. Yamamoto, and H. Fukuda Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 11 2009 1063 1069
15. J. Sakamoto, K. Chin, and K. Kondo Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer Anticancer Drugs 17 2 2006 231 236
16. Y.S. Hong, S.Y. Song, and S.I. Lee A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer Ann Oncol 15 9 2004 1344 1347
17. W. Koizumi, M. Kurihara, S. Nakano, and K. Hasegawa Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 3 2000 191 197
18. Y.H. Kim, S.K. Cheong, and J.D. Lee Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma Am J Clin Oncol 19 2 1996 212 216
19. W. Koizumi, H. Narahara, and T. Hara S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 3 2008 215 221
20. A. Ohtsu, Y. Shimada, and K. Shirao Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205) J Clin Oncol 21 1 2003 54 59
21. S.E. Al-Batran, J.T. Hartmann, and S. Probst Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 26 9 2008 1435 1442
22. S.H. Park, W.K. Lee, and M. Chung Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil Anticancer Drugs 17 2 2006 225 229
23. Imamura H, Iishi I, Tsuburaya A, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). In: ASCO gastrointestinal cancers symposium, Chicago; 2008.
24. M. Dank, J. Zaluski, and C. Barone Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction Ann Oncol 19 8 2008 1450 1457
25. D. Cunningham, A.F. Okines, and S. Ashley Capecitabine and oxaliplatin for advanced esophagogastric cancer New Engl J Med 362 9 2010 858 859
26. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III stduy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). In: ASCO annual meeting, 2009, Orlando. J Clin Oncol 2009;LBA4509.
27. A.L. Schechter, D.F. Stern, and L. Vaidyanathan The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 312 5994 1984 513 516
28. A.L. Schechter, M.C. Hung, and L. Vaidyanathan The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor Science 229 4717 1985 976 978
29. S. Cohen Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal J Biol Chem 237 1962 1555 1562
30. M. Das, T. Miyakawa, and C.F. Fox Specific radiolabeling of a cell surface receptor for epidermal growth factor Proc Natl Acad Sci USA 74 7 1977 2790 2794
31. C. Shih, L.C. Padhy, M. Murray, and R.A. Weinberg Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts Nature 290 5803 1981 261 264
32. T. Akiyama, C. Sudo, H. Ogawara, K. Toyoshima, and T. Yamamoto The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 4758 1986 1644 1646 (Pubitemid 16095607)
33. L. Coussens, T.L. Yang-Feng, and Y.C. Liao Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 4730 1985 1132 1139
34. D. Baeckstrom, D. Alford, and J. Taylor-Papadimitriou Morphogenetic and proliferative responses to heregulin of mammary epithelial cells in vitro are dependent on HER2 and HER3 and differ from the responses to HER2 homodimerisation or hepatocyte growth factor Int J Oncol 16 6 2000 1081 1090
35. R. Worthylake, L.K. Opresko, and H.S. Wiley ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors J Biol Chem 274 13 1999 8865 8874
36. M.A. Olayioye, D. Graus-Porta, and R.R. Beerli ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner Mol Cell Biol 18 9 1998 5042 5051
37. R. Pinkas-Kramarski, L. Soussan, and H. Waterman Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions Embo J 15 10 1996 2452 2467 (Pubitemid 26151185)
38. K.L. Carraway 3rd, M.X. Sliwkowski, and R. Akita The erbB3 gene product is a receptor for heregulin J Biol Chem 269 19 1994 14303 14306
39. G.D. Plowman, J.M. Green, and J.M. Culouscou Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 Nature 366 6454 1993 473 475
40. L. Sepp-Lorenzino, I. Eberhard, and Z. Ma Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells Oncogene 12 8 1996 1679 1687
41. J.M. Daly, M.A. Olayioye, and A.M. Wong NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways Oncogene 18 23 1999 3440 3451
42. C.R. King, M.H. Kraus, and S.A. Aaronson Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 4717 1985 974 976
43. T. Yamamoto, S. Ikawa, and T. Akiyama Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor Nature 319 6050 1986 230 234 (Pubitemid 16128786)
44. J. Yokota, T. Yamamoto, and K. Toyoshima Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo Lancet 1 8484 1986 765 767
45. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 1989 707 712
46. Y. Yonemura, I. Ninomiya, and A. Yamaguchi Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer Cancer Res 51 3 1991 1034 1038
47. H. Grabsch, S. Sivakumar, S. Gray, H.E. Gabbert, and W. Muller HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series Cell Oncol 32 1-2 2010 57 65
48. M. Risio, G. De Rosa, and I. Sarotto HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples Int J Oncol 23 5 2003 1381 1387
49. M. Kimura, H. Tsuda, and D. Morita A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements Virchows Arch 445 3 2004 255 262
50. M. Hofmann, O. Stoss, and D. Shi Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 7 2008 797 805
51. Bang Y, Chung H, Xu J, et al. Seoul National University Hospital, Seoul, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Affiliated Hospital (307 Hospital) Cancer Centre, Beijing, China; National Centre for Tumour Diseases, Heidelberg, Germany; Aichi Cancer Center, Nagoya, Japan; Bashkirian Republican Clinical Oncology Dispensary, Ufa, Russia; F. Hoffmann-La Roche, Basel, Russia; Roche Products Ltd., Welwyn Garden City, United Kingdom; TARGOS Molecular Pathology GmbH, Kassel, Germany; University Hospital Gasthuisberg, Leuven, Belgium. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009;27(suppl):15s [abstract 4556].
52. B.M. Fendly, M. Winget, and R.M. Hudziak Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product Cancer Res 50 5 1990 1550 1558
53. M.C. Hancock, B.C. Langton, and T. Chan A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines Cancer Res 51 17 1991 4575 4580
54. P.G. Kasprzyk, S.U. Song, P.P. Di Fiore, and C.R. King Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies Cancer Res 52 10 1992 2771 2776
55. P. Carter, L. Presta, and C.M. Gorman Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 10 1992 4285 4289
56. Y. Matsui, M. Inomata, and M. Tojigamori Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model Int J Oncol 27 3 2005 681 685
57. M. Tanner, M. Hollmen, and T.T. Junttila Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 2 2005 273 278
58. S.J. Gong, C.J. Jin, S.Y. Rha, and H.C. Chung Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines Cancer Lett 214 2 2004 215 224
59. K. Fujimoto-Ouchi, F. Sekiguchi, and H. Yasuno Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models Cancer Chemother Pharmacol 59 6 2007 795 805
60. Nicholas G, Cripps C, Au H-J, et al. Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2. In: ESMO. Ann Oncol, 2006 [abstract 1105].
61. Rech J, Arnold D, Folprecht G, Hejna M, Hofmann M, Gramatzki M. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER2-positive gastric cancer. In: ESMO. Ann Oncol, 2006 [abstract 1096].
62. Cortés-Funes H, Rivera F, Alés I, et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. In: 2007 ASCO annual meeting proceedings part I. J Clin Oncol 2007;4613.
63. A. Seidman, C. Hudis, and M.K. Pierri Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 5 2002 1215 1221
64. M.S. Ewer, M.T. Vooletich, and J.B. Durand Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 31 2005 7820 7826
65. M.S. Ewer, and S.M. Lippman Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 13 2005 2900 2902
66. M.E. Billingham, J.W. Mason, M.R. Bristow, and J.R. Daniels Anthracycline cardiomyopathy monitored by morphologic changes Cancer Treat Rep 62 6 1978 865 872
67. B. Mackay, M.S. Ewer, C.H. Carrasco, and R.S. Benjamin Assessment of anthracycline cardiomyopathy by endomyocardial biopsy Ultrastruct Pathol 18 1-2 1994 203 211
68. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy New Engl J Med 339 13 1998 900 905
69. M. Ryberg, D. Nielsen, and T. Skovsgaard Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer J Clin Oncol 16 11 1998 3502 3508
70. M. Untch, M. Muscholl, and S. Tjulandin First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial J Clin Oncol 28 9 2010 1473 1480
71. Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. In: 2010 Gastrointestinal cancers symposium, Orlando; 2010. p. 7.
72. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 2007 118 145
73. Y.K. Kang, W.K. Kang, and D.B. Shin Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 4 2009 666 673
74. U. Vanhoefer, P. Rougier, and H. Wilke Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 14 2000 2648 2657
75. D. Cameron, M. Casey, and M. Press A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Res Treat 112 3 2008 533 543
76. C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer New Engl J Med 355 26 2006 2733 2743
77. J.W. Kim, H.P. Kim, and S.A. Im The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines Cancer Lett 272 2 2008 296 306
78. M.J. LaBonte, P.C. Manegold, and P.M. Wilson The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38 Int J Cancer 125 12 2009 2957 2969
79. Z.A. Wainberg, A. Anghel, and A.J. Desai Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo Clin Cancer Res 16 5 2010 1509 1519
80. Iqbal S, Goldman B, Lenz HJ, Fenoglio-Preiser CM, Blanke CD. S0413: a phase II SWOG study of GW572016 (lapatinib) as first-line therapy in patients (pts) with advanced or metastatic gastric cancer. In: 2007 ASCO annual meeting proceedings part I, Chicago. J Clin Oncol 2007;4621.
81. Hecht JR, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. In: Gastrointestinal cancers symposium; 2008 [abstract 43].
82. Y. Nagata, K.H. Lan, and X. Zhou PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2 2004 117 127
83. L.H. Saal, K. Holm, and M. Maurer PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 65 7 2005 2554 2559
84. K. Berns, H.M. Horlings, and B.T. Hennessy A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 4 2007 395 402
85. S. Diermeier, G. Horvath, and R. Knuechel-Clarke Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation Exp Cell Res 304 2 2005 604 619
86. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (herceptin) J Natl Cancer Inst 93 24 2001 1852 1857
87. G. von Minckwitz, A. du Bois, and M. Schmidt Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study J Clin Oncol 27 12 2009 1999 2006
88. I. Smith, M. Procter, and R.D. Gelber 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 9555 2007 29 36
89. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer New Engl J Med 353 16 2005 1659 1672
90. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer New Engl J Med 353 16 2005 1673 1684
91. Wolmark N, Yothers G, O'Connell MJ, et al. Allegheny General Hospital, Pittsburgh, PA. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. In: ASCO annual meeting, 2009, Orlando. J Clin Oncol, 2009.
92. M. Tateishi, T. Toda, Y. Minamisono, and S. Nagasaki Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma J Surg Oncol 49 4 1992 209 212
93. T. Ohguri, Y. Sato, W. Koizumi, K. Saigenji, and T. Kameya An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 53 1 1993 75 79
94. T. Mizutani, M. Onda, A. Tokunaga, N. Yamanaka, and Y. Sugisaki Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer Cancer 72 7 1993 2083 2088
95. K. Motojima, J. Furui, and N. Kohara ErbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection Surgery 115 3 1994 349 354
96. H.R. Lee, J.H. Kim, and H.D. Uhm Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain Oncology 53 3 1996 192 197
97. M. Nakajima, H. Sawada, and Y. Yamada The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas Cancer 85 9 1999 1894 1902
98. H. Allgayer, R. Babic, and K.U. Gruetzner C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems J Clin Oncol 18 11 2000 2201 2209
99. J. Pinto-de-Sousa, L. David, and R. Almeida C-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma Int J Surg Pathol 10 4 2002 247 256